Heart Test Laboratories Inc
NASDAQ:HSCS

Watchlist Manager
Heart Test Laboratories Inc Logo
Heart Test Laboratories Inc
NASDAQ:HSCS
Watchlist
Price: 1.98 USD -1% Market Closed
Market Cap: $6.3m

P/E

-0.7
Current
20%
Cheaper
vs 3-y average of -0.9

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
-0.7
=
Market Cap
$7.2m
/
Net Income
$-8.5m

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
-0.7
=
Market Cap
$7.2m
/
Net Income
$-8.5m

Valuation Scenarios

Heart Test Laboratories Inc is trading above its industry average

If P/E returns to its Industry Average (27.6), the stock would be worth $-73.52 (3 813% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-3 813%
Maximum Upside
No Upside Scenarios
Average Downside
3 496%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple -0.7 $1.98
0%
Industry Average 27.6 $-73.52
-3 813%
Country Average 22.9 $-60.94
-3 178%

Forward P/E
Today’s price vs future net income

Not enough data available to calculate forward P/E

Market Distribution

Lower than 100% of companies in the United States of America
Percentile
0th
Based on 8 489 companies
0th percentile
-0.7
Low
0 — 15.3
Typical Range
15.3 — 33.2
High
33.2 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 15.3
Median 22.9
70th Percentile 33.2
Max 1 826 183.3

Heart Test Laboratories Inc
Glance View

Market Cap
6.3m USD
Industry
Health Care

Heart Test Laboratories Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Southlake, Texas and currently employs 12 full-time employees. The company went IPO on 2022-06-15. Heart Test Laboratories, Inc. is a medical technology company focused on developing artificial intelligence (AI) based technology to an electrocardiogram (ECG) to expand and improve an ECG’s clinical usefulness. The Company’s product candidate, the MyoVista wavECG, or the MyoVista, is designed to provide diagnostic information related to cardiac dysfunction. The MyoVista is a 12-lead resting ECG device that features its algorithm developed to detect cardiac dysfunction in the diastolic phase, specifically slower than normal left ventricular relaxation rates. The MyoVista uses electrical information from the heart captured during a standard resting 12-lead ECG test as inputs to an artificial intelligence-based algorithm. The MyoVista detects whether a patient is negative or positive for abnormally slow left ventricular diastolic relaxation rates.

HSCS Intrinsic Value
1.65 USD
Overvaluation 17%
Intrinsic Value
Price $1.98
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett